PUNE, India, Dec. 29, 2021 /PRNewswire/ — In line with the evolving offerings by Easebuzz in Digital Payments and Collections space, the company announced the launch of its new visual identity and brand logo. The all-new brand identity underscores the commitment of Easebuzz to solve complex business problems around Payments Collections and Payouts.
A fintech company headquartered in Pune, Easebuzz is offering Digital Payment Collections & Payout Solutions to small, medium and large businesses of Indian Economy with SaaS based APIs. Easebuzz offers core financial and ancillary services to help firms digitize their business transactions, collections, and settlements. Some of its successful offerings include: Payment Gateway, Payment Links, Wire, Automated Teller, Fee reconciliation software, APIs to manage subscription-based payments etc. Available both as a web and mobile application, Easebuzz is dedicated to creating APIs that help include fintech services within your existing software or ERP system.
“This new identity personifies our commitment in supporting businesses with Secure. Cutting-edge. Comprehensive APIs. custom designed for each of the leading sectors of Indian Economy,” said Amit Kumar, CTO & Director at Easebuzz.
With exploding digitization of services and digital commerce post covid, Easebuzz has seen significant growth in Revenues and is currently catering to 60,000+ Businesses including brands like BigBasket, BBdaily, Just Dial, Symbiosis International University, Akshaya Patra and more.
“The rebranding marks a new Easebuzz with a strategy focused on Low cost – high value solutions for businesses across E-commerce, Insurance, Education, Retail, Mutual Funds and other leading sectors. With strong Security Framework, Sector-specific API Product suite and energetic brand, Easebuzz is onwards in achieving its vision of helping a Million Businesses with Seamless Payment Solutions,” said Rohit Prasad, MD & CEO at Easebuzz.
Designed to work effortlessly across digital and physical channels, the new logo is formed with 3 forward moving rays, symbolizing the alphabet “E” and 3 brand values – simplicity, Speed, and Reliability. The rays are stacked in a sturdy and solid construction to represent a brand with a strong foundation and comprehensive temperament. The Prime Blue, Mint Green and Violet Blue shades of the logo underscores the brand’s belief in Security, Innovation and Comprehensive Solution approach.
“There is lot of excitement around the Easebuzz in the market. This new brand identity captures that story and positions the company as forward looking & cutting-edge brand solving complex business problems in the Payments Space,” said Bharath Katta, VP & Head of Marketing at Easebuzz.
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)
Easebuzz has also been recently recognized as Most Promising Company at India Achievers Awards 2021.
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)
Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp).
The virus is incapable of developing resistance to favipiravir even with long-term exposure on infected cells, as has been confirmed in clinical trials. This provides Avifavir® with a major advantage not only over highly specific biologics but also over many other similar nucleoside products.
ChemRar Group announces the Russian Avifavir® (INN: favipiravir) drug is effective against various variants of SARS-CoV-2 (coronavirus), including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp) via three complementary mechanisms, resulting in complete blockade of the viral infection.
In addition, the virus is incapable of developing resistance to favipiravir even with long-term exposure on infected cells, as has been confirmed in clinical trials. This provides Avifavir® with a major advantage not only over highly specific biologics but also over many other similar nucleoside products prone to inducing rapid evolution of resistant clinical variants.
The problem of rapid mutation is particularly typical of RNA viruses, such as SARS-CoV-2 (coronavirus). Most of the mutations are found in the spike protein structure, in particular in two of its key parts that are recognized by the human immune system.
A meta analysis of 23 COVID-19 treatment studies for favipiravir is demonstrating a 47% improvement when favipiravir is used in early treatment of coronavirus. This analysis is available at: https://c19favipiravir.com/meta.html
Figure. Mechanism of Antiviral Action of Avifavir® (INN: favipiravir)
In June 2020, with the support of the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), ChemRar Group specialists developed and were the first in the world to release Avifavir® (INN: favipiravir), a direct antiviral for COVID-19 treatment, to the Russian and international markets. The product’s efficacy has been confirmed in a full-scale clinical trial in Russia involving 460 COVID patients. Avifavir® has been supplied to more than 15 countries around the world.
Clinical trials of Avifavir® have demonstrated its anti-COVID properties, such as alleviating symptoms and cut the duration of the disease by half compared to standard therapy.
In particular:
Avifavir® is demonstrating the best results in COVID treatment when used in the first 3-5 days after first symptoms;
After the first 4 days of treatment, 65 % of patients on Avifavir® tested negative for coronavirus, twice the rate of the standard treatment group. By day 10, the number of negative patients had reached 90 %;
In 68 % of patients on Avifavir®, body temperature normalized earlier (on Day 3) compared to the control group (on Day 6).
Median time to clinical improvement with Avifavir® was 7 days vs. 10 days in the standard treatment group.
In addition, the results of Avifavir® in patients with COVID-19 are being closely monitored in real-world clinical practice. A retrospective review of favipiravir’s efficacy and safety is currently under way in 40,000 patients exposed to the product in an outpatient or inpatient setting.
In 2020–2021, potential of favipiravir against coronavirus infection was actively investigated in more than 50 clinical trials involving around 5,000 patients in Russia, Japan, China, India, Thailand, Turkey, Iran, Saudi Arabia, EU countries and Latin America. To date, the PubMed database of international medical and biological literature contains almost 900 peer-reviewed favipiravir-related papers. At least 700 of them were published in the last 1.5 years. These publications speak for the high efficacy and safety of favipiravir against COVID-19.
Elena Yakubova, Medical Director of ChemRar Group, commented:
“Having accumulated extensive experience with Avifavir® in patients infected with COVID both from clinical trials and real-world clinical practice, we see that taking Avifavir® in the first 3–5 days after infection leads to a milder disease in most cases and prevents hospitalization. Over the past 17 months, more than 4 million patients have been treated with favipiravir worldwide. The product was well tolerated with no new adverse events, which confirms the high safety of favipiravir”.
To date, vast body of information has been accumulated in the scientific literature on various aspects of the favipiravir pharmacology as the product has been well studied, including its mechanisms of action, activity in vitro and in vivo, clinical efficacy, safety, cost-effectiveness, potential for combination therapy, analytical control methods, etc. A series of clinical trials in 2020-2021 have provided objective evidence for the efficacy and safety of favipiravir as treatment for COVID-19.
If therapy begins in the first days after the onset of disease, the product significantly increases survival rate, reduces viral load, need for artificial ventilation, and length of hospital stay.
Robert Redfield, a renowned American virologist and former director of the U.S. Center for Disease Control and Prevention (2018–2021), notes: “Avifavir® has been shown to be effective against COVID-19 in clinical trials and medical practice. Recently additional direct acting antiviral have been developed. Studying the combination of Avifavir® with other antivirials such as Paklovid (Pfizer) could offer even better therapeutic options for those at higher risk of COVID-19 disease progression, reduce the likelihood of drug-resistant virus mutations, and increase the time after diagnosis when therapy can be effective”.
References to studies supporting the efficacy of favipiravir against COVID-19:
In a multicenter randomized phase II/III clinical trial in patients with moderate COVID-19 (NCT04434248), Avifavir provided effective clearance of SARS-CoV-2 virus in 62.5 % of patients within 4 days, was safe and well tolerated (Ivashchenko А.А. et al. Avifavir for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021 Aug 2;73(3):531-534. doi: 10.1093/cid/ciaa1176.). Now we can summarise and supplement both the ChemRar Group data on the use of the product and the findings of extensive scientific research with the product performed around the world.
A systematic meta-analysis of 11 clinical trials has demonstrated that favipiravir causes effective clearance of the SARS-CoV-2 virus by day 7 and promotes clinical improvement within 14 days (Manabe et al. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21(1):489.).
In a randomized, blind, placebo-controlled phase III study of favipiravir efficacy and safety in 156 COVID-19 patients with moderate-to-severe pneumonia (Japan), the median time to patient recovery was 11.9 days in the favipiravir group and 14.7 days in the placebo group, with a statistically significant difference (p = 0.0136) (Shinkai M. et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther. 2021 Aug 27; 1-21.).
Inclusion of favipiravir in the national COVID-19 treatment protocol in Turkey resulted in a pronounced, statistically significant decrease in ICU hospitalization rates from 24 % to 12 % (Guner et al. ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol. North Clin Istanb. 2021; 8(2):119.).
In a retrospective study conducted in specialized public hospitals in Saudi Arabia, the median time to discharge for patients with COVID-19 was 10 days in the favipiravir group compared to 15 days in the maintenance therapy group, across all grades of COVID-19 severity (Alamer et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis/ Curr Med Res Opin. 2021; 37(7):1085.).
In a randomized, open-label, parallel, multicenter phase III study of 150 patients with mild to moderate COVID-19 conducted in India, the median time to cessation of virus excretion was 5 days versus 7 days, and the median time to clinical recovery was 3 days versus 5 days for favipiravir and control, respectively (Udwadia et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021; 103:62.).
Favipiravir has demonstrated efficacy and safety in treatment of mild to moderate COVID-19 in outpatients and hospitalized patients: the median time to clinical improvement was 6.0 days (IQR 4.0; 9.3) in the favipiravir group and 10.0 (IQR 5.0; 21.0) days in the SOC group. The rate of viral elimination on Day 5 in the favipiravir group was significantly higher than in SOC group: 81.2% vs. 67.9% (RR 1.22; 05% CI 1.00-1.48; P=0.022). (Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19. Am J Transl Res 2021;13(11):12575-12587)
Redefining the future of AI-powered intelligent automation and process discovery
BANGALORE, India, Dec. 24, 2021 /PRNewswire/ — Automation Anywhere, a global leader in robotic process automation (RPA), today announced that it has entered into a definitive agreement to acquire cloud pioneer FortressIQ, a leading process discovery and mining company based in San Francisco.
Combining FortressIQ with Automation Anywhere will usher in a new era of intelligent automation by enabling organizations to accelerate automation initiatives and transform in a digital-first world.
“The Fortress IQ team are the pioneers of process intelligence, making this a perfect match,” said Mihir Shukla, CEO and Co-Founder, Automation Anywhere. “Together, Automation Anywhere and FortressIQ will reshape the future of automation, changing the way our customers automate, adapt, and accelerate as they pursue digital transformation initiatives. I’m thrilled to welcome FortressIQ to the Automation Anywhere family once the transaction closes.”
“Automation Anywhere is a global leader of the RPA revolution, and nearly two decades later, is reimagining automation to be cloud-native, intelligent, and designed for every person in every company,” said Pankaj Chowdhry, CEO and Founder, FortressIQ. “We share a vision to deliver and automate at scale, as well as share common values to help customers succeed on a trusted platform. This will change the industry, and I’m excited about what we can automate next.”
Building the Automated Company, Together
Demand for robotic process automation has skyrocketed as the pandemic endures and companies look for new ways to streamline business processes. Process intelligence, as part of RPA, is essential, helping companies identify, map, and analyze the multi-dimensional processes that extend across hundreds of applications and hundreds of thousands of employees.
With the acquisition of FortressIQ, Automation Anywhere will advance its AI-powered, cloud-native Automation 360 platform with process discovery, intelligence, and optimization that can scale to any system or application across any vertical. The new capabilities offer built-in intelligence that provides fast, accurate visibility on which processes can and should be automated.
“Today, organizations are focusing on improving cycle times and overall operating performance to ensure that inefficiency does not get in the way of successful transformation,” said Maureen Fleming, Program Vice President, IDC Intelligent Process Automation Research. “Tools aimed at providing insights about where a process and its individual tasks are holding back overall operating performance are becoming the de facto starting point for automation and improvement projects. Integrating process insights with automation planning and development speeds up time to value while improving the accuracy and completeness of the resulting automation.”
Automating low-value, manual tasks can free up time and resources that can then be used by organizations to adapt to changing business conditions. Automation Anywhere customers have collectively implemented nearly 3 million automations, with leading companies deploying tens of thousands of bots throughout their organizations, primarily in the cloud.
Automation Anywhere is the world’s #1 cloud automation platform, delivering intelligent RPA solutions globally across all industries to automate end-to-end business processes, for the fastest path to enterprise transformation. The company offers the world’s only cloud-native platform combining RPA, artificial intelligence, machine learning, and analytics to automate repetitive tasks and build enterprise agility, freeing up humans to pivot to the next big idea, build deeper customer relationships and drive business growth. For additional information, visit www.automationanywhere.com.
Automation Anywhere and Automation 360 are trademarks/service marks or registered trademarks/service marks of Automation Anywhere, Inc. in the United States and other countries.
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)
WATCHO, the new and fastest-growing OTT platform from Dish TV India Limited, India’s leading DTH Company, has premiered a new nail-biting crime series “Jaunpur” to end the year 2021 with a bang. Inspired by the life story of a well-known gangster who shot to the top in JAUNPUR, this crime thriller is sure to keep its audience at the end of their seats. The series also explores the human side of one of the most-wanted gangsters of UP. Shot extensively in Jaunpur, the new web series is available in Hindi and is now available on the WATCHO app and website.
The action-packed series is directed by Satish Shukla which follows the story of Babu, a brave and fun-loving teenager who gets into the world of crime to save his friend’s honor. It explores Babu’s journey as he gets transformed into one of Jaunpur’s most dreaded figures. Produced by Abhishek Bindal, the series stars Anuj Sharma, Palak Singh, and Zahid M Shah as its main cast.
Commenting on the launch, Mr. Sukhpreet Singh, Corporate Head – Marketing, DishTV & WATCHO, Dish TV India Ltd. said, “Close on the footsteps of ‘Papa Ka Scooter’, we are very excited to bring to our audience another WATCHO original from the Hindi hinterland. JAUNPUR explores the dark underbelly of UP and is a story of crime, action, family, and sacrifice. Inspired by real-life events, this gripping tale boasts of an outstanding cast, power-packed performances, and an intense storyline, which is sure to make our audience sit up and take notice.”
Bringing in a unique assortment of snackable content cutting across all genres, WATCHO offers many original shows including web series like Papa Ka Scooter, Aghaat, Cheaters – The Vacation, Sarhad, Mystery Dad, JaalSaazi, Titli-Current Maarti Hai, It’s My Pleasure, 4 Thieves, Love Crisis, Ardhsatya, Mortuary, Chhoriyan, Rakhta Chandana. There are also original influencer shows like Look I Can Cook, Bikhare hain Alfaaz, etc. to name a few. Available across screens (Android & iOS devices, Dish SMRT devices, D2H Magic devices, and Fire TV Stick) and at www.WATCHO.com, WATCHO presently provides over 35 plus original shows, 150 plus exclusive plays, and 100 plus live channels in Hindi, Kannada, and Telugu regional languages.
Company receives top honors for creating the best customer experience and delivering the best return on investment to its global customers
LIVONIA, Mich., Dec. 22, 2021 /PRNewswire/ — Today, the first global provider of integrated employee experience and workforce management solutions, WorkForce Software, has been positioned in the top category as an Exemplary Vendor in Ventana Research’s 2022 Value Index on Workforce Management. The index is a quantified, research-based evaluation of technology providers and products. The report recognizes WorkForce Software as a Value Index Leader for six distinct areas: Overall, Capability, Customer Experience, TCO/ROI, Usability, and Reliability.
This Value Index assesses 13 vendors’ products using Ventana Research’s methodology and blueprint, evaluating software in seven key categories that are weighted to reflect buyers’ needs based on their expertise and research. The Value Index is designed to ensure that it provides objective research and guidance to organizations looking to assess and evaluate their applications for business and IT needs.
Workforce management continues to garner additional investment and focus as businesses across all industries recognize the importance of digitally transforming their workforce management and employee communication systems. Ventana Research emphasizes that an explosion of technology innovation associated with leveraging AI/ML and embedded analytics in many areas of a business, including a range of HCM processes and operations, and a major reframing of the employer/employee relationship stemming from the widespread emphasis on elevating the employee experience (EX), are two significant trends for businesses. Their research team points out that this was becoming more of a strategic focus across most organizations before the pandemic, but the last two years have made delivering a great EX an essential part of operating a business. They caution that in the absence of this, employees tend to become disengaged, and many will leave. The same can be true of the customers serviced by those workers.
“Modern workforce management technology is increasingly viewed as critical for creating an engaged and inclusive workforce,” says Steve Goldberg, VP and Research Director, HCM at Ventana Research. “Innovative software companies like WorkForce Software also deliver competitive advantage by helping customers materially elevate organizational agility and collaboration.”
To support the needs of businesses looking for a modern solution to elevate and improve their EX, WorkForce Software introduced enhancements to its WorkForce Suite in June of this year that delivered new capabilities to create dramatically better employee experiences leveraging data and advanced analytics to meet the needs of modern workers and to quickly deliver valuable results to its global customers.
“WorkForce Software’s leadership position in Ventana Research’s Workforce Management Value Index confirms our commitment to consistently deliver valuable solutions to our customers,” says Joe Ross, Chief Product Officer at WorkForce Software. “Our dedicated teams at WorkForce Software are committed to ensuring our customers are able to solve real challenges and realize a return on their software investment. We are driven to create the best modern workforce management solution with EX and AI, delivered on a modern cloud platform, and connecting people wherever they are, no matter if they work behind a desk or have a critical deskless role interfacing with customers or delivering goods and services.”
WorkForce Software is the first global provider of workforce management solutions with integrated employee experience capabilities. The company’s WorkForce Suite adapts to each organization’s needs—no matter how unique their pay rules, labor regulations, and schedules—while delivering a breakthrough employee experience at the time and place work happens. Enterprise-grade and future-ready, WorkForce Software is helping some of the world’s most innovative organizations optimize their workforce, protect against compliance risks, and increase employee engagement to unlock new potential for resiliency and optimal performance. Whether your employees are deskless or office workers, unionized, full-time, part-time, or seasonal, WorkForce Software makes managing your global workforce easy, less costly, and more rewarding for everyone. For more information, please visit www.workforcesoftware.com.
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)
The Gamaleya Center’s preliminary laboratory study shows that Sputnik V demonstrates high virus neutralizing activity (VNA) against the Omicron (B.1.1.529) variant and is expected to provide strong defense against severe disease and hospitalization.
The study was conducted using sera with a long period after vaccination (more than 6 months after vaccination) as an indicator of Sputnik V’s long-lasing protection.
Sputnik V elicits strong and long-lasting T-cell response, and as 80% of epitopes in the spike protein are not affected by the mutations in the Omicron variant, Sputnik V is expected to provide long-lasting protection against severe disease by Omicron. Sputnik V’s long-lasting T-cell immunity contributes to 80% efficacy against Delta on months 6-8.
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination. Virus neutralizing activity against Omicron 2-3 months after a Sputnik Light booster in this preliminary laboratory study is higher than VNA against the wild-type virus 6 months after Sputnik V vaccination. Based on these data the expected efficacy of Sputnik V with Sputnik Light booster against Omicron infection could be more than 80%, as Sputnik V showed efficacy of more than 80% against wild-type virus 6 month after vaccination.
100% of individuals revaccinated with Sputnik Light as a booster developed neutralizing antibodies against Omicron and demonstrated their high level 2-3 months after the revaccination.
Sputnik Light booster is expected to provide strong protection against infection, severe disease and hospitalization by Omicron. Sputnik Light booster is recommended to strengthen efficacy of vaccines against Omicron. Boosting by Sputnik Light can strengthen and lengthen the quickly waning efficacy of many vaccines in light of combined Delta and Omicron challenge.
Sputnik Light is a universal booster to other vaccines, including Sputnik V. In Argentina, a combination of Sputnik Light with other vaccines has demonstrated its effectiveness as a universal booster inducing stronger antibody and T-cell response compared to a two-shot homologous regimen.
Sputnik V and Sputnik Light were developed on the basis of a safe and well-studied over 30 years technology and have not been associated with rare serious side effects as myocarditis or pericarditis.
The highest safety and efficacy of Sputnik V and Sputnik Light was demonstrated in more than 30 studies and real-world data publications from more than 10 countries.
New Delhi, December 22, 2021 – Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), investor in Sputnik V and Sputnik Light vaccines, announced an article “Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant” has been published in medRxiv (the preprint server for health sciences) and is available at:
The preliminary study by the Gamaleya Center has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster (based on human adenovirus serotype 26, the first component of Sputnik V) are effective against Omicron (B.1.1.529) variant of COVID, providing for better protection when compared to other vaccines. Heterologous boosting with Sputnik Light is the solution to increase other vaccines’ efficacy, including against Omicron, and extend the booster protection period.
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response.
Sputnik Light booster is recommended to strengthen efficacy of vaccines against Omicron. Boosting by Sputnik Light as well as heterologous boosting can strengthen and lengthen the quickly waning efficacy of many vaccines in light of combined Delta and Omicron challenge.
Sputnik Light has already been registered in more than 25 countries as a standalone vaccine and a universal booster to other vaccines helping to increase their efficacy (including in Argentina, UAE, Bahrain, Philippines, and San Marino). Sputnik V has been authorized in 71 countries with total population of over 4 billion people.
Sputnik Light has already shown strong results used as a booster in mix & match trials in Argentina. A combination of Sputnik Light with vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino, conducted in 5 provinces (City and Province of Buenos Aires, as well as Córdoba, La Rioja and San Luis) has demonstrated that Sputnik Light induces stronger antibody and T-cell response as compared to homologous regimen (two shots of the same vaccine). Each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on the 14th day after administering a second dose when compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.
Sputnik Light efficacy data:
Sputnik Light has been proven to be safe and highly effective by real-world vaccination data. In particular, data from the Ministry of Health of Buenos Aires (Argentina) has demonstrated standalone efficacy of Sputnik Light between 78.6-83.7% among the elderly (over 40,000 people of 60-79 years old), which is higher than that of many two-dose vaccines.
Findings by the Gamaleya Center based on data collected in Moscow have demonstrated Sputnik Light vaccine administered standalone has 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75% effective among subjects under the age of 60. Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events following vaccination, such as myocarditis or pericarditis.
Urges farmers to enroll in the Pradhan Mantri Fasal Bhima Yojana scheme to protect the crops
SBI General, one of India’s leading General Insurance company has been a part of the Pradhan Mantri Fasal Bima Yojana initiative since the last 7 years. The company has constantly been on ground supporting farmers with all the necessary assistance required during the entire insurance journey right from enrolment to claims.
The general Insurer has 29 districts insured for Rabi crops and 39 districts insured for the kharif crops across the five States of Rajasthan, Karnataka, Himachal Pradesh, Uttarakhand and Assam under the Pradhan Mantri Fasal Bima Yojana (PMFBY) and Restructured Weather Based Crop Insurance Scheme (RWBCIS).
The company has conducted various on ground awareness activities to educate farmers about the benefits of insurance and protection the scheme offers during standing crop, preventing sowing/planting risks, covering post-harvest losses, throughout the complete crop cycle. For the Rabi season, SBI General Insurance supports coverage for various crops like tomatoes, potatoes, mangoes, pomegranate, chili, grape, barley, wheat, gram, masoor, cumin, fenugreek, mustard, malta, orange, peach and litchi.
SBI General has commenced its enrolment for farmers to get their crops insured in each State along with add on covers pertaining to the climatic conditions. It provides hailstorm covers in Karnataka for Mango, Pomegranate, Chilli, Pepper, Papaya, Ginger and Acid Lime crops, and for Apple trees in Himachal Pradesh.
Mr. P.C Kandpal, MD and CEO, SBI General Insurance, said, “Agriculture is the core of India, and we are glad to have the reach and opportunity to educate the farmer communities across the country on Pradhan Mantri Fasal Bima Yojana and make it available to them. Ahead of the Rabi season, we urge the farmers and encourage them adopt innovative and modern agricultural practices. We want to reach out to as many farmers as possible to educate them on the importance of crop insurance and securing their produce. At SBI General Insurance, we are extremely proud of our farmer community and our aim is to expand and help as many farmers under the Pradhan Mantri Fasal Bhima Yojana as possible.”
More and more countries are using Sputnik Light as a standalone vaccine and as a universal booster, including against Omicron variant.
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced 7 million doses of Sputnik Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global delivery of the one-shot vaccine.
Demand for Sputnik Light is increasing as more countries are using it as a standalone vaccine and a universal booster for other vaccines, including against the latest Omicron variant of coronavirus.
Sputnik Light is based on human adenovirus serotype 26 (the first component of Sputnik V). It has already been registered in more than 20 countries as a standalone one-shot vaccine and a universal booster to other vaccines (including in Argentina, UAE, Bahrain, Philippines, and San Marino).
Recent preliminary study announced by Gamaleya Institute showed that Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron. According to Gamaleya Institute:
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination. Virus neutralizing activity against Omicron 2-3 months after a Sputnik Light booster in this preliminary laboratory study is higher than VNA against the wild-type virus 6 months after Sputnik V vaccination. Based on these data the expected efficacy of Sputnik V with Sputnik Light booster against Omicron infection could be more than 80%, as Sputnik V showed efficacy of more than 80% against wild-type virus 6 month after vaccination.
100% of individuals revaccinated with Sputnik Light as a booster developed neutralizing antibodies against Omicron and demonstrated their high level 2-3 months after the revaccination.
Sputnik Light booster is expected to provide strong protection against infection, severe disease and hospitalization by Omicron.
Sputnik Light booster is recommended to strengthen efficacy of vaccines against Omicron. Heterologous boosting with Sputnik Light is the solution to strengthen and lengthen the quickly waning efficacy of many vaccines, including against Omicron, and extend the booster protection period.
Sputnik V standalone also induces robust neutralizing antibody response to Omicron variant, which is further strengthened by Sputnik Light booster.
Sputnik V elicits strong and long-lasting T-cell response, and as 80% of epitopes in the spike protein are not affected by the mutations in the Omicron variant, Sputnik V is expected to provide long-lasting protection against severe disease by Omicron. Sputnik V’s long-lasting T-cell immunity contributes to 80% efficacy against Delta on months 6-8 compared with efficacy of less than 29% demonstrated by certain mRNA vaccines after 6 months.
In Argentina, a combination of Sputnik Light with other vaccines has demonstrated its effectiveness as a universal booster inducing stronger antibody and T-cell response compared to a two-shots homologous regimen. A combination of Sputnik Light with vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino, conducted in 5 provinces (City and Province of Buenos Aires, as well as Córdoba, La Rioja and San Luis) has demonstrated that each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on the 14th day after administering a second dose when compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.
Sputnik Light efficacy data:
Sputnik Light has been proven to be safe and highly effective by real-world vaccination data. In particular, data from the Ministry of Health of Buenos Aires (Argentina) has demonstrated standalone efficacy of Sputnik Light between 78.6-83.7% among the elderly (over 40,000 people of 60-79 years old), which is higher than that of many two-dose vaccines.
Findings by the Gamaleya Center based on data collected in Moscow have demonstrated Sputnik Light vaccine administered standalone has 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75% effective among subjects under the age of 60.
Sputnik Light and Sputnik V were developed on the basis of a safe and well-studied over 30 years technology and have not been associated with rare serious side effects as myocarditis or pericarditis.
Sanjay Rai Sherpuria’s this book will become a guiding path for Hindu culture to the modern generation.
Thousands of saints and lakhs of Hindus gathered in Mahakumbh at Chitrakoot.
The Sangh chief called for unity among Hindus.
Hindus have to be Himalayas: Swami Rambhadracharya
”Only the Hindus unity will pave the way for human welfare in the world.” Today, the huge forum of Hindu Ekta Mahakumbh organized in Chitrakoot has given many such important messages to the world. In the same forum, Sir Sangh Chalak Mohan Bhagwat of Rashtriya Swayamsevak Sangh also released Sanjay Rai Sherpuria’s book Hindu Dharma Ki Dharohar, Bhartiye Sanskriti.
He said that the title itself gives a comprehensive introduction to this book. What is Sanatan Hindu Dharma and how it is continuously functioning as an invaluable treasure of Indian culture? These facts are the basis of this book. He further said, “Words like Yagya, Havan, Shankh, Padma, Cow, Trishul, Mandir, Devasthan is in Sanatan Hindu Vedic culture only. These are not only words, but the pronunciation of these words itself reflects that what is the secret of life and life itself? What are our Gods, Goddesses and religious symbols? Why and how much important they are?
The way the society is changing and many worship systems are evolving in the world. In such an environment, if anyone wants to know and understand Hindu culture, they must read this book of Sanjay Rai Sherpuria. The manner in which the eternal symbols have been presented in the form of rosary of beads in this book is amazing. All the major facts, elements and symbols are present in this book to understand Indianness, culture and Hindu heritage. This book is such a key that will play an efficient role in connecting the future generations to their origins and understanding Hindu culture.
The Hindu Ekta Mahakumbh at Lord Shri Ram’s Sankalp Bhoomi Chitrakoot concluded today with great happiness and new energy in the grand presence of thousands of saints and lakhs of Hindu community. The convener of this event was Tulsi Peeth’s successor Acharya Ramchandra Das and patron Dharmachakravarti Tulsipeethadhishwar Swami Rambhadracharyaji. Today many messages were given to the world in the matter of Hindutva from this vast platform.
Organized under the patronage of Tulsi Peethadheeshwar, Padmavibhushan, Jagadguru Swami Rambhadracharya, in this Mahakumbh the Sarsangh Chalak Mohan Bhagwat of Rashtriya Swayamsevak Sangh was the chief guest of the program. Sri Sri Ravi Shankar, Sadhvi Ritambara, Swami Chidanand Muni, Ramesh Bhai Ojha, Ramvilas Das Vedanti and almost all saints and sages of India’s Sanatan Vedic Hindu tradition were present on the occasion.
This event has been organized at a time when various types of conspiracies are being planned against Hindu culture in the country and the world. With the abolition of Article 370 in Kashmir, the construction of the huge Shri Ram temple in Ayodhya, the construction of Baba Vishwanath Corridor in Kashi, the salvation of Lord Shri Krishna Janasthali in Mathura, etc many remarkable works have progressed. Divisive conspiracies of caste, sect and creed are being done to break the unity of Hindus. In such a time, this event is important in many ways. This is an attempt to acquaint the world with the vast nature of Hindutva.
In this event, an attempt was made to give a message that all the representatives of Samagra Hindutva should join in and strengthen social unity by giving the message of Hindu unity from one platform. In this event, apart from the saints, an attempt was also made to represent the socio-cultural identity of the country.
Mr. Zac Hollis, Brand Director, ŠKODA AUTO India, said, “The decision to increase prices from January 1, 2022 is a result of the rising input costs and increased operational costs. Despite the macro-economic challenges, we have worked to ensure that the customer impact in terms of the incremental price increase is minimal. We will continue to offer the best in quality and value, as we look to build the ŠKODA brand in India.”
